Leukotriene Receptor Antagonists (LTRAs) are a class of medications that are commonly used for the treatment of asthma and other respiratory conditions. These drugs work by blocking the action of leukotrienes, which are chemicals produced by the body's immune system that cause inflammation and constriction of the airways.
Leukotrienes are responsible for various allergic and inflammatory responses in the airways, causing symptoms such as wheezing, coughing, and shortness of breath. LTRAs are specifically designed to target and inhibit the activity of leukotriene receptors, which are present on the surface of cells in the airways and other tissues.
By blocking the leukotriene receptors, LTRAs effectively prevent the binding of leukotrienes to these receptors. This action helps to reduce inflammation, relax and widen the airways, and alleviate symptoms of respiratory conditions, particularly asthma.
These drugs are typically administered orally in the form of tablets or granules, with regular dosing schedules depending on the specific medication. LTRAs are often used as an add-on therapy to other asthma medications, such as inhaled corticosteroids, to provide additional symptom relief or as an alternative treatment option for patients who cannot tolerate other medications.
Common examples of LTRAs include montelukast, zafirlukast, and pranlukast. While generally well-tolerated, LTRAs may have side effects such as headache, gastrointestinal disturbances, or liver function abnormalities, although these are rare.
In conclusion, Leukotriene Receptor Antagonists are medications that work by blocking the action of leukotrienes, providing relief from inflammation and constriction of the airways in conditions like asthma.
